Background The present studies evaluated the association between admission glucose and adverse outcomes of people with coronary artery disease（CAD） after primary percutaneous coronary intervention（PCI）, but the ef...Background The present studies evaluated the association between admission glucose and adverse outcomes of people with coronary artery disease（CAD） after primary percutaneous coronary intervention（PCI）, but the effects of glucose control levels on these patients＇ outcomes are not fully studied, and the prognostic value of hemoglobin A1c（Hb A1c） for a better survival is still uncertain. Methods Our study included 440 patients with CAD undergoing the PCI therapy after admission, and who were divided into 2groups, one had Hb A1 c ≤ 6.5%（n = 309）, the other 〉 6.5%（n = 131）. Then, we gave these patients clinical follow-ups at the first, third, sixth, twelfth month respectively after PCI. Results There were no significant differences between the two groups at the baseline characteristics and the drugs taken by the patients after PCI. But we found that the outcomes of major adverse cardiac events（MACEs） were significantly better in Hb A1 c ≤6.5% group than in Hb A1 c 〉 6.5% group（P = 0.016） according to the COX multivariate regression analysis. Conclusion The MACE-free survival after PCI is significantly better when Hb A1 c is≤ 6.5% than Hb A1 c is 〉 6.5%.展开更多
基金supported by Foundation of the Nature Science of Guangdong Province(No.10151008002000002)
文摘Background The present studies evaluated the association between admission glucose and adverse outcomes of people with coronary artery disease（CAD） after primary percutaneous coronary intervention（PCI）, but the effects of glucose control levels on these patients＇ outcomes are not fully studied, and the prognostic value of hemoglobin A1c（Hb A1c） for a better survival is still uncertain. Methods Our study included 440 patients with CAD undergoing the PCI therapy after admission, and who were divided into 2groups, one had Hb A1 c ≤ 6.5%（n = 309）, the other 〉 6.5%（n = 131）. Then, we gave these patients clinical follow-ups at the first, third, sixth, twelfth month respectively after PCI. Results There were no significant differences between the two groups at the baseline characteristics and the drugs taken by the patients after PCI. But we found that the outcomes of major adverse cardiac events（MACEs） were significantly better in Hb A1 c ≤6.5% group than in Hb A1 c 〉 6.5% group（P = 0.016） according to the COX multivariate regression analysis. Conclusion The MACE-free survival after PCI is significantly better when Hb A1 c is≤ 6.5% than Hb A1 c is 〉 6.5%.
